Equities

XSpray Pharma AB (publ)

XSpray Pharma AB (publ)

Actions
  • Price (SEK)77.70
  • Today's Change77.70 / --
  • Shares traded1.03k
  • 1 Year change+134.03%
  • Beta--
Data delayed at least 20 minutes, as of Jul 10 2024 10:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments166120272
Total Receivables, Net4.172.592.50
Total Inventory448.556.20
Prepaid expenses3.570.931.48
Other current assets, total--0.000.00
Total current assets218132282
Property, plant & equipment, net1086545
Goodwill, net------
Intangibles, net437386296
Long term investments0.000.000.00
Note receivable - long term3.023.00--
Other long term assets--0.00--
Total assets765585623
LIABILITIES
Accounts payable121517
Accrued expenses161110
Notes payable/short-term debt000
Current portion long-term debt/capital leases4.861.572.05
Other current liabilities, total6.261.040.65
Total current liabilities402930
Total long term debt320.561.19
Total debt372.133.23
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities722931
SHAREHOLDERS EQUITY
Common stock312321
Additional paid-in capital1,216907813
Retained earnings (accumulated deficit)(554)(374)(242)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.19)----
Total equity693556592
Total liabilities & shareholders' equity765585623
Total common shares outstanding322321
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.